BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 33663063)

  • 21. Clinical Characteristics and Predictive Outcomes of Recurrent Nasopharyngeal Carcinoma-A Lingering Pitfall of the Long Latency.
    Chen YH; Luo SD; Wu SC; Wu CN; Chiu TJ; Wang YM; Yang YH; Chen WC
    Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion after intensity-modulated radiotherapy.
    Fei Z; Xu T; Qiu X; Li M; Chen T; Li L; Huang C; Chen C
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2047-2055. PubMed ID: 33392660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detecting plasma Epstein-Barr virus DNA to diagnose postradiation nasopharyngeal skull base lesions in nasopharyngeal carcinoma patients: a prospective study.
    Liang FY; Sun W; Han P; Lu X; Lian YN; Huang XM
    Chin J Cancer; 2012 Mar; 31(3):142-9. PubMed ID: 22237037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of MR imaging to detect residual versus recurrent nasopharyngeal carcinoma following treatment with radiation therapy.
    Lin GW; Wang LX; Ji M; Qian HZ
    Eur J Radiol; 2013 Dec; 82(12):2240-6. PubMed ID: 24103355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
    Zhang Y; Tang LL; Li YQ; Liu X; Liu Q; Ma J
    Int J Cancer; 2019 May; 144(9):2313-2319. PubMed ID: 30485420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
    Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Image-based diagnosis of residual or recurrent nasopharyngeal carcinoma may be a phantom tumor phenomenon.
    Lee CC; Lee JC; Huang WY; Juan CJ; Jen YM; Lin LF
    Medicine (Baltimore); 2021 Feb; 100(8):e24555. PubMed ID: 33663063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How successful is high-dose (> or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma?
    Teo PM; Kwan WH; Chan AT; Lee WY; King WW; Mok CO
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):897-913. PubMed ID: 9531376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A collision tumor of nasopharyngeal carcinoma and primary mantle cell lymphoma in the nasopharynx: a case report and review of the literature.
    Jiang M; Yuan XP; Zhang H; Li CQ; Mao YL; Chen WL
    BMC Oral Health; 2023 Sep; 23(1):672. PubMed ID: 37718438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current treatment options for local residual nasopharyngeal carcinoma.
    Stoker SD; van Diessen JN; de Boer JP; Karakullukcu B; Leemans CR; Tan IB
    Curr Treat Options Oncol; 2013 Dec; 14(4):475-91. PubMed ID: 24243165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of locally recurrent nasopharyngeal carcinoma.
    Lee AWM; Ng WT; Chan JYW; Corry J; Mäkitie A; Mendenhall WM; Rinaldo A; Rodrigo JP; Saba NF; Strojan P; Suárez C; Vermorken JB; Yom SS; Ferlito A
    Cancer Treat Rev; 2019 Sep; 79():101890. PubMed ID: 31470314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nasopharyngeal carcinoma.
    Brennan B
    Orphanet J Rare Dis; 2006 Jun; 1():23. PubMed ID: 16800883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRI detection of suspected nasopharyngeal carcinoma: a systematic review and meta-analysis.
    Gorolay VV; Niles NN; Huo YR; Ahmadi N; Hanneman K; Thompson E; Chan MV
    Neuroradiology; 2022 Aug; 64(8):1471-1481. PubMed ID: 35499636
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.